Trial Profile

Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 14 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pamrevlumab (Primary)
Indications Idiopathic pulmonary fibrosis
Focus Registrational; Therapeutic Use
Acronyms ZEPHYRUS 2; Zephyrus II
Sponsors FibroGen

Most Recent Events

04 Feb 2024 This trial has been Discontinued in Italy, according to European Clinical Trials Database record
26 Jun 2023 Status changed from active, no longer recruiting to discontinued based on results from ZEPHYRUS-1 trial
10 May 2023 This trial has been completed in Poland, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com